Publicaciones en las que colabora con María Rosa López Huertas (41)

2024

  1. Corrigendum to: “Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D” [Biomed. Pharmacother. 150 (2022) 1−11] (Biomedicine & Pharmacotherapy (2022) 150, (S0753332222003547), (10.1016/j.biopha.2022.112965))

    Biomedicine and Pharmacotherapy

2022

  1. Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort

    PLoS ONE, Vol. 17, Núm. 8 August

  2. Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Vol. 150, pp. 112965

  3. Dynamics of HIV Reservoir and HIV‐1 Viral Splicing in HCV‐Exposed Individuals after Elimination with DAAs or Spontaneous Clearance

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  4. Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers

    Frontiers in immunology, Vol. 13, pp. 848886

  5. Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission

    Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-21

  2. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU

    Frontiers in Immunology, Vol. 12

  3. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity

    Frontiers in Immunology, Vol. 12

2020

  1. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection

    Biochemical Pharmacology, Vol. 182

  2. Hepatitis C virus influences HIV-1 viral splicing in coinfected patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-18

2019

  1. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

    Scientific Reports, Vol. 9, Núm. 1

  2. The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection

    PLoS Pathogens, Vol. 15, Núm. 8

  3. Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV

    Current HIV/AIDS Reports, Vol. 16, Núm. 5, pp. 414-422

2018

  1. Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 156, pp. 248-264

2017

  1. Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells

    PLoS ONE, Vol. 12, Núm. 10

  2. The CCR5-Antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-Agonist Bryostatin-1

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells

    Biochemical Pharmacology, Vol. 106, pp. 30-45

  2. IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle

    Cell Reports, Vol. 14, Núm. 9, pp. 2100-2107

  3. PKCθ and HIV-1 transcriptional regulator Tat co-exist at the LTR promoter in CD4+ T cells

    Frontiers in Immunology, Vol. 7, Núm. FEB